X4 Pharmaceuticals is a BUY, driven by a funded Phase 3 trial, current product pipeline, and a strong cash position extending ...

F rom blockbuster drugs that garner media attention to smaller innovations that help millions maintain health, the biotech and pharmaceutical industries have an impact on everyone’s life. Meanwhile, ...

Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has dropped an early-stage candidate for advanced cancers from its pipeline. | Ono Pharmaceutical subsidiary Deciphera Pharmaceuticals has ...

Dublin, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The "Major Pharmaceutical Companies" directory has been added to ResearchAndMarkets.com's offering. Essential for those doing business in the global ...

The commercial-stage biotechnology company held a ceremony Jan. 30 at its new facility at 200 Connell Drive to mark the ...

In an effort to battle against what members feel is an existential threat to their business, a group of 10 domestic biotech companies have launched the Midsized Biotech Alliance of America with a ...

From billion-dollar licensing deals to advances in cancer therapies and artificial intelligence, Chinese biotech firms are ...

Dublin, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The "African Pharmaceutical Directory" directory has been added to ResearchAndMarkets.com's offering. Keep up-to-date with the African Pharmaceutical Industry ...

We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential. In this article, we are going to take a look at where Ultragenyx Pharmaceutical, Inc. (NASDAQ:RARE) stands ...

This biotech powerhouse could maintain its strength for the long term.

Dublin, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The "South and Central American Pharmaceutical Directory" directory has been added to ResearchAndMarkets.com's offering. Keep up-to-date with the Latin ...

North Carolina, ranked in the top five states for life sciences by Business Facilities, is home to a thriving ecosystem specializing in bio and pharmaceutical manufacturing. Propelled by a low cost of ...